Form 8-K - Current report:
SEC Accession No. 0001628280-23-037827
Filing Date
2023-11-08
Accepted
2023-11-08 16:05:59
Documents
14
Period of Report
2023-11-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vnda-20231108.htm   iXBRL 8-K 36284
2 EX-99.1 vnda8-k1182023exhibit991.htm EX-99.1 111199
6 vandaq32019earningsca_imaga.jpg GRAPHIC 49643
  Complete submission text file 0001628280-23-037827.txt   358765

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20231108.xsd EX-101.SCH 1953
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20231108_lab.xml EX-101.LAB 24851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20231108_pre.xml EX-101.PRE 13084
8 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20231108_htm.xml XML 2834
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 231387790
SIC: 2834 Pharmaceutical Preparations